Cancer Pain Market Anticipates Steady 5.46% CAGR Through 2030

Cancer Pain Market Snapshot

“The Cancer Pain Market is estimated to increase at a CAGR of 5.46% from $ 7.78 Billion in 2023 to $ 9.95 Billion by 2030.”

Cancer pain is a common side effect of cancer, often linked to various oncology disorders. The nature of cancer pain is influenced by the type, phases, and interventions used in cancer treatment, such as targeted therapy and chemotherapy. The growth of tumors on bones, nerves, and organs causes pain.

Cancer pain management is constantly seeking innovative treatments, despite the abundance of available options. Industry players are using the network model in R&D to develop new treatments. This allows businesses to evaluate the efficacy of new therapy combinations.

Around 70% of the medications under development are quick-dose lifestyle medications, biologics, and tailored treatments, reflecting a shift in the sector.

Can cancer pain be relieved?

Pain is not a common symptom of cancer, but it is treatable in all cases. Doctors can help manage and minimize discomfort, and healthcare teams are better equipped to treat patients if they know how to report and discuss pain effectively. Full relief may not always be possible.

>>>Download Sample Report Now:https://marketreportservice.com/request-sample/cancer-pain-market-54661 

Key Points

• Cancer, treatment, or diagnostic tests can cause pain.
• Pain can be effectively managed before, during, and after tests and procedures.
• Different cancer treatments may result in specific types of pain.
• Peripheral neuropathy is a type of pain that can be triggered by chemotherapy.
• Cancer pain can significantly impact the quality of life and ability to function even after the end of treatment.
• Pain control can significantly enhance your overall quality of life.
• Each patient requires a unique plan to manage their cancer pain.

Growth Drivers

Advancements in health technology are improving cancer pain management effectiveness and accessibility through improved medication delivery systems, tailored treatments, and pain management strategies.

Increased healthcare spending makes pain management medications and treatments more accessible, promoting market expansion.

The aging population and widespread sedentary lifestyle are driving the market expansion, with the proportion of Americans 65 and older expected to rise from 16% in 2019 to 21.6% by 2040.

This growth is attributed to the rising incidence of cancer and its discomfort, as over 1 in 4 adults globally, or 28%, lead sedentary lifestyles, affecting 1.4 billion people.

As cancer becomes more prevalent, public awareness of the illness and its suffering increases, leading to an increase in the cost of diagnosing and treating cancer-related pain.

The OECD reports that healthcare spending in sixteen OECD nations increased to 9.9% of GDP in 2020, indicating that rising costs and government assistance will drive international market expansion.

Restraints

The rising cost of prescription drugs is hindering the growth of the cancer pain market, as many patients receive inadequate care due to the high cost and lack of access in developing countries.

The article discusses the potential negative effects of painkillers.

The market expansion for painkillers may be hindered by the risk of drug tolerance, dependence, and various adverse effects.

The stigma surrounding opioid use is a significant issue that needs to be addressed.

The widespread use of opioid-based pain treatments may be hindered by concerns about opiate abuse and addiction.

Market Trends

overview of personalized pain management.

Cancer pain management is undergoing significant changes due to the growing emphasis on personalized treatment plans based on molecular and genetic profiles.

overview of various multimodal approaches.

The integration of various pain management strategies, including pharmaceutical and non-pharmacological methods, is gaining popularity for addressing distinct aspects of pain.

Opportunities

The incidence of cancer is on the rise.

The CDC predicts that by 2026, the number of cancer survivors is expected to rise to over 20 million. The National Cancer Institute reports that 20-50% of cancer patients experience discomfort, affecting the market for cancer pain.

The market is expanding due to the increasing availability of various drugs. Aspirin-like medications are commonly used to treat inflammation and bone-related pain, but they can cause gastrointestinal issues like bleeding and indigestion.

Paracetamol is crucial for managing cancer-related discomfort, as it doesn't damage the stomach, doesn't thin the blood, and is well-tolerated. It reduces fever and improves bone pain, and is often taken with opioids, supporting market expansion.

Cancer Pain Market Segment Analysis

Analysis by Drug Type

In 2022, the opioids segment dominated the market due to the increasing incidence of cancer-related severe pain, the use of opioids for pain treatment, and a healthy supply. However, the non-opioids industry is expected to grow significantly due to affordability and broad availability of these drugs.

The opioids category dominates due to the increasing prevalence of severe cancer-related pain and the growing use of opioids as pain management tools. The robust pipeline for opioid-based medications reinforces its relevance.

However, the non-opioids segment is expected to expand due to their easy availability and cost-effectiveness, making them a desirable choice for patients with mild to moderate cancer pain. This will significantly impact their market traction during the projection period.

Analysis by Disease Indication

In 2022, lung cancer dominated the market for cancer pain due to the increasing incidence of lung cancer cases, pain associated with lung cancer, and the availability of effective analgesics designed to address this type of pain, which is expected to continue during the forecast period.

The market for pain treatment in lung cancer is driven by the increasing incidence and associated pain problems. The need for focused techniques has led to the introduction of specific analgesics that effectively target the distinct pain patterns associated with lung cancer. 

Competitive Landscape of the Cancer Pain Market Analysis

• Pfizer (USA)
• Johnson & Johnson (USA)
• Purdue Pharma (USA)
• Novartis (Switzerland)
• Heron Therapeutics (USA)
• Teva Pharmaceutical Industries (Israel)
• Eli Lilly and Company (USA)
• AstraZeneca (UK)
• GlaxoSmithKline (UK)
• Merck & Co., Inc. (USA)

New Developments in Cancer Pain Market

Oct 26, 2023- Novartis confirms unconstrained supply for Pluvicto® and continues to significantly expand the number of treatment centers

October 26, 2023 — Novartis announced that the US Food and Drug Administration has classified the Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) drug shortage status as resolved. This determination is the result of efforts to significantly scale up production of Pluvicto that have more than doubled weekly production capacity since May. Novartis is committed to providing a consistent, reliable supply of Pluvicto and making this important medicine readily available to patients.

October 12, 2023- U.S. FDA Approves Pfizer’s BRAFTOVI® + MEKTOVI® for BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test.1BRAF V600Emutations can be assessed from either plasma or tumor tissue using the FoundationOne Liquid CDx or the FoundationOne CDx FDA-approved companion diagnostic tests, respectively.

In April 2023, Pfizer announced the approval of Lyrica (pregabalin) for the management of neuropathic pain associated with cancer.

February 16, 2023 Pfizer Announces Positive TALZENNA® and XTANDI® Combination Data from Phase 3 TALAPRO-2 Study

In March 2023, the FDA approved Insys Therapeutics' Subsys (fentanyl) sublingual spray for the management of breakthrough pain in adults with cancer who are already receiving and are tolerant to opioid therapy.

In February 2023, the FDA granted breakthrough therapy designation to Ceregene's CTX-001 for the treatment of chronic pain associated with solid tumors.

In January 2023, the FDA approved the first non-opioid drug for the management of cancer pain.

Regional Analysis of Global Cancer Pain Industry

North America's dominant position in the cancer pain market in 2022 is expected to continue due to factors such as rising cancer cases, technological advancements, easy access to pain management treatments, and excellent chemotherapy options. These elements work together to support North America's continued prominence in the market for cancer pain.

The Asia-Pacific region is expected to experience the highest CAGR of 5.8% in cancer pain management due to factors such as rising cancer prevalence, increasing senior citizens, and increased awareness of early cancer screening.

Effective pain relief techniques are in high demand due to these factors, and the region is positioning itself as a major player in determining the future of cancer pain management. The region's growth in the cancer pain industry is driven by these factors, making it a crucial player in the global healthcare landscape.

Segments Covered in the Cancer Pain Market Report

Segment by Drug

• Opioids
• Morphine
• Fentanyl
• Non-opioids
• Acetaminophen
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
• Nerve Blockers

Segment by Disease Indication

• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Blood Cancer
• Others

Market by Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Australia
  • Rest of Asia-Pacific
• Rest of the World
• Middle East
• Africa
• Latin America

Frequently Asked Questions

What is the expected growth rate of the Cancer Pain market over the next 7 years?

The Cancer Pain Market is estimated to increase at a CAGR of 5.46% from $ 7.78 Billion in 2023 to $ 9.95 Billion by 2030.

Who are the major players in the Cancer Pain market and what is their market share?

Pfizer (USA), Johnson & Johnson (USA), Purdue Pharma (USA), Novartis (Switzerland), Heron Therapeutics (USA), Teva Pharmaceutical Industries (Israel),Eli Lilly and Company (USA),AstraZeneca (UK),GlaxoSmithKline (UK),Merck & Co., Inc., are prominent players operating and dominating in the market.

Who are the top 3 Cancer Pain Market Key Vendors?

Pfizer (USA), Johnson & Johnson (USA), Purdue Pharma (USA), Novartis (Switzerland), are key players in the Cancer Pain market.

Which geographical areas dominate the worldwide market for Cancer Pain?

North America region are emerging as the top regional markets for Cancer Pain solutions.

1.SUMMARY

1.1. Cancer Pain Market Overview

1.2. Key Insights

1.3. Report Scope

1.4. Research Methodology

1.5. Frequently Asked Questions

1.6. Chapter Outlines

2. DECISION-MAKING SUMMARY
3. INTRODUCTION

3.1. Overview of Cancer Pain

3.2. Key Historical Events

3.3. Structure

3.4. Biochemical Interaction

3.5. Target Indications

3.6. Advantages of Cancer Pain

3.7 Challenges associated with Cancer Pain

3.8. Future Perspectives.

4. MARKET LANDSCAPE

4.1. Methodology

4.2 Cancer Pain: Developer Landscape

4.2.1. Analysis by Year of Establishment

4.2.2. Analysis by Company Size

4.2.3. Analysis by Location of Headquarters (Region-wise)

4.2.4. Analysis by Location of Headquarters (Country-wise)

4.2.5. Analysis by Year of Establishment, Company Size and Location of Headquarters (Region-wise)

4.2.6. Most Active Players

5. COMPANY

5.1. Company Overview

5.1.2 Management Team

5.1.3. Product Portfolio

5.1.4. Recent Developments and Future Outlook

6. PARTNERSHIPS AND COLLABORATIONS

6.1. Partnership Models

6.2. Cancer Pain: Partnerships and Collaborations

6.2.1. Analysis by Year of Partnership

6.2.2. Analysis by Type of Partnership

6.2.3. Analysis by Year and Type of Partnership

6.2.4. Analysis by Type of Partner

6.2.5. Analysis by Year of Partnership and Type of Partner

6.2.6. Analysis by Type of Partnership and Type of Partner

6.2.7. Analysis by Type of Partner and Parent Company Size

7. ACADEMIC GRANTS ANALYSIS

7.1. Methodology and Key Parameters

7.2. Cancer Pain: Academic Grants Analysis

7.2.1. Analysis by Year of Grant Award

7.2.2. Analysis by Amount Awarded

7.2.3. Analysis by Funding Institute Center

7.2.4. Analysis by Support Period

7.2.5. Analysis by Funding Institute Center and Support Period

7.2.6. Analysis by Type of Grant Application

7.2.7. Analysis by Purpose of Grant

8. PUBLICATION ANALYSIS

8.1. Analysis Methodology and Key Parameters

8.2. Cancer Pain: Publication Analysis

8.2.1. Analysis by Year of Publication

8.2.2. Analysis by Type of Publication

8.2.3. Analysis by Type of Conjugate

8.2.4. Analysis by Target Indication

8.2.5. Analysis by Copyright Holder

8.2.6. Word Cloud: Emerging Focus Area

8.2.7. Most Active Publishers: Analysis by Number of Publications

9. SUCCESS PROTOCOL ANALYSIS

9.1. Methodology and Key Parameters

9.2. Key Assumptions and Scoring Criteria

9.3. Success Protocol Analysis

9.4. Assessment of Approved Cancer Pain

10. Appendix 1: Tabulated Data
11. Appendix 2: List of Companies

1. Pfizer (USA)
2. Johnson & Johnson (USA)
3. Purdue Pharma (USA)
4. Novartis (Switzerland)
5. Heron Therapeutics (USA)
6. Teva Pharmaceutical Industries (Israel)
7. Eli Lilly and Company (USA)
8. AstraZeneca (UK)
9. GlaxoSmithKline (UK)
10. Merck & Co., Inc. (USA)

Research Methodology